Relapsed/Refractory Large B-cell Lymphoma Clinical Trials Database - Free Access to 4 Studies
Access comprehensive clinical trial information for Relapsed/Refractory Large B-cell Lymphoma through Pure Global AI's free database. This collection includes 4 clinical trials across multiple phases including Phase 1, Phase 1/2, Phase 2. Currently, 3 trials are actively recruiting participants.
Research for Relapsed/Refractory Large B-cell Lymphoma is being conducted in United States of America, Australia and more. Leading sponsors include Kite, A Gilead Company and Peter MacCallum Cancer Centre, Australia. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Pure Global AI provides free access to 4 clinical trials studying Relapsed/Refractory Large B-cell Lymphoma, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 2+ countries.
Top research sponsors include Kite, A Gilead Company, Peter MacCallum Cancer Centre, Australia, among others.